10-K: Hypha Labs Shifts Focus to Mushroom Bioreactors After Asset Sale; Faces Going Concern Uncertainty

Hypha Labs, formerly Digipath, transitions to developing mushroom bioreactors after selling its cannabis testing assets, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Hypha Labs, formerly Digipath, sold its cannabis testing assets on February 20, 2024, and is now focused on developing and commercializing a home bioreactor for producing functional mushrooms.
• The company's mission is to provide an easy-to-use device, the Hypha Micropearl bioreactor, that produces enriched mycelium of functional mushrooms in eight days.
• The global market for functional mushrooms was estimated at $34.75 billion in 2024 and is projected to reach $65.83 billion by 2030, with a CAGR of 11.2%.
• Hypha Labs has filed two U.S. patent applications related to machine learning algorithms for mycelium processing.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern due to recurring net losses and insufficient cash reserves.
• As of January 13, 2025, Hypha Labs had seven employees.
• The company plans to market the Micropearl bioreactor by the end of calendar year 2025.
• As of March 31, 2024, the aggregate market value of the registrant’s common stock held by non-affiliates was approximately $2,051,031.
• As of January 13, 2025, there were 126,546,825 shares of registrant’s common stock outstanding.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While the company is entering a growing market, the auditor's going concern warning and the company's need for additional financing raise significant concerns.

Positives

• Hypha Labs is entering a growing market for functional mushrooms, projected to reach $65.83 billion by 2030.
• The company's bioreactor technology aims to simplify and reduce the cost of mushroom production.
• Hypha Labs is seeking patent protection for its innovative mycelium processing methods.
• The company intends to offer a subscription service to its users, where they can have regularly scheduled deliveries to their homes of replacement cartridges which will offer savings compared to one-off purchases.

Negatives

• The auditor's report expresses substantial doubt about Hypha Labs' ability to continue as a going concern.
• The company has a limited operating history in its current business.
• Hypha Labs will require substantial additional financing to achieve its goals.
• The company is dependent on a limited number of customers initially.
• The company may not be successful in developing the Hypha Micropearl bioreactor and introducing any new and improved models of the device.

Risks

• Hypha Labs may be unable to obtain additional capital required to implement its business plan.
• The company's limited operating history in its current business makes it difficult to evaluate its current business and future prospects.
• The company will initially be dependent on a limited number of customers.
• The company may not be successful in developing the Hypha Micropearl bioreactor and introducing any new and improved models of the device.
• Macroeconomic trends including inflation and rising interest rates may adversely affect our financial condition and results of operations.
• The company's business is dependent on general economic conditions and consumer discretionary spending.
• The company's internal information technology systems may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could disrupt our business or result in the loss of critical and confidential information.
• The company may need to devote significant resources to protect against cybersecurity breaches or to address problems caused by breaches, diverting resources from the growth and expansion of our business.
• The company may choose to rely upon manufacturers based in outside the United States, including China, and their operations are subject to risks associated with business operations in those countries.
• The company may rely on a limited number of suppliers, or in some cases, a single supplier, for some of the components of our Hypha Micropearl bioreactor, such as the cartridges, and may not be able to find replacements or immediately transition to alternative suppliers
• The company may be unable to develop, optimize, operate and manage our fulfillment centers
• Significant merchandise returns could harm our business.
• The company is subject to risks related to online payment methods.
• The company's plans are dependent upon key individuals and the ability to attract qualified personnel.
• If the market for our products does not develop or become sustainable, or becomes saturated, our revenues may fail to materialize, and our financial condition and results of operations could be materially impaired.
• If the company is unable to protect our intellectual property rights, our business, competitive position, financial condition and results of operations could be materially and adversely affected.
• The company has outstanding shares of preferred stock with rights and preferences superior to those of our common stock.
• The company plans to increase the amount of authorized shares of our common stock and our preferred stock.
• The company has not paid dividends in the past and do not expect to pay dividends in the future.

Future Outlook

The company plans to continue product design and development of its Micropearl bioreactor, with the goal of commercializing the bioreactor device by the end of calendar year 2025. The Company will seek to raise funds to complete the development and testing of its bioreactor over the next 6 to 12 months and to fund the initial launch of commercial sales of its bioreactor device.

Industry Context

The company is shifting from the cannabis testing industry to the functional mushroom market, which is projected to experience significant growth. The company faces competition from existing mushroom-based product manufacturers and companies exploring novel cultivation techniques.

Comparison to Industry Standards

• The document mentions Four Sigmatic, Mushroom Perfecti, Natures Rise, Lifeway Foods, Inc., and Applied Food Sciences Inc. (AFS) as competitors or companies in the functional mushroom space.
• Optimi Health Corp., a Canadian-based company, opened a new mushroom research and development facility, consisting of two 10,000-square-feet facilities with ten growing rooms producing approximately 2,000 kilograms of dried psilocybin mushrooms a month.

Related Party Transactions

• During the years ended September 30, 2024 and 2023 the Company incurred compensation expense of $ 60,000 and $ 60,000 for services provided by its CFO.
• During the years ended September 30, 2024 and 2023 the Company incurred fees of $ 24,000 and $ 34,000 for services provided by its directors.
• During the year ended September 30, 2024, the Company granted 6,000,000 shares of its common stock to the directors as compensation for services performed with a fair value of $ 112,200 .
• During the year ended September 30, 2023, the Company granted 3,400,000 and 1,400,000 shares of its common stock to the officers and directors as compensation for services performed with a fair value of $ 24,820 and $ 9,860 , respectively.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional financing and the auditor's going concern warning.
• Employees face uncertainty due to the company's financial instability.
• Customers may be impacted by potential delays in product development and commercialization.

Next Steps

• Continue product design and development of the Micropearl bioreactor.
• Produce a limited number of bioreactors for testing purposes.
• Seek a manufacturing arrangement outside the United States.
• Raise funds to complete development and testing and fund the initial launch of commercial sales.

Key Dates

Keywords

Hypha Labs, bioreactor, functional mushrooms, mycelium, cannabis testing, patent applications, going concern, Micropearl, Digipath